Keywords: gtc, 3rd-qtr, net, loss, narrows, 1m, drug
GTC's 3rd-qtr net loss narrows to $6.1M
Article | 17 November 2008
US drug developer GTC Biotherapeutics' net loss for the third quarter of 2008 totaled $6.1 million, or $0.06 per share, compared with $8.4 million, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- Italy's pharma market slump set to continue, warns GlobalData
